725 related articles for article (PubMed ID: 31003450)
1. Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation.
Yang J; Fernández-Galilea M; Martínez-Fernández L; González-Muniesa P; Pérez-Chávez A; Martínez JA; Moreno-Aliaga MJ
Nutrients; 2019 Apr; 11(4):. PubMed ID: 31003450
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
Spooner MH; Jump DB
Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):103-110. PubMed ID: 30601174
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
Kelley NS
Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
[TBL] [Abstract][Full Text] [Related]
5. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD.
Nobili V; Alisi A; Musso G; Scorletti E; Calder PC; Byrne CD
Crit Rev Clin Lab Sci; 2016; 53(2):106-20. PubMed ID: 26463349
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids.
Spahis S; Alvarez F; Ahmed N; Dubois J; Jalbout R; Paganelli M; Grzywacz K; Delvin E; Peretti N; Levy E
J Nutr Biochem; 2018 Aug; 58():28-36. PubMed ID: 29864682
[TBL] [Abstract][Full Text] [Related]
7. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.
Jump DB; Depner CM; Tripathy S; Lytle KA
Adv Nutr; 2015 Nov; 6(6):694-702. PubMed ID: 26567194
[TBL] [Abstract][Full Text] [Related]
8. Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease.
Alberti G; Gana JC; Santos JL
Nutrients; 2020 Nov; 12(11):. PubMed ID: 33212947
[TBL] [Abstract][Full Text] [Related]
9. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
Caldwell S
Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials.
Chen LH; Wang YF; Xu QH; Chen SS
Clin Nutr; 2018 Apr; 37(2):516-521. PubMed ID: 28040302
[TBL] [Abstract][Full Text] [Related]
11. Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
Suzuki-Kemuriyama N; Matsuzaka T; Kuba M; Ohno H; Han SI; Takeuchi Y; Isaka M; Kobayashi K; Iwasaki H; Yatoh S; Suzuki H; Miyajima K; Nakae D; Yahagi N; Nakagawa Y; Sone H; Yamada N; Shimano H
PLoS One; 2016; 11(6):e0157580. PubMed ID: 27333187
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials.
Guo XF; Yang B; Tang J; Li D
Clin Nutr; 2018 Feb; 37(1):113-122. PubMed ID: 28161092
[TBL] [Abstract][Full Text] [Related]
13. Substitution of linoleic acid with α-linolenic acid or long chain n-3 polyunsaturated fatty acid prevents Western diet induced nonalcoholic steatohepatitis.
Jeyapal S; Kona SR; Mullapudi SV; Putcha UK; Gurumurthy P; Ibrahim A
Sci Rep; 2018 Jul; 8(1):10953. PubMed ID: 30026586
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA.
Delarue J; Lallès JP
Mol Nutr Food Res; 2016 Jan; 60(1):147-59. PubMed ID: 26300318
[TBL] [Abstract][Full Text] [Related]
15. Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight.
Okada LSDRR; Oliveira CP; Stefano JT; Nogueira MA; Silva IDCGD; Cordeiro FB; Alves VAF; Torrinhas RS; Carrilho FJ; Puri P; Waitzberg DL
Clin Nutr; 2018 Oct; 37(5):1474-1484. PubMed ID: 29249532
[TBL] [Abstract][Full Text] [Related]
16. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
17. Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease.
Valenzuela R; Ortiz M; Hernández-Rodas MC; Echeverría F; Videla LA
Curr Med Chem; 2020; 27(31):5250-5272. PubMed ID: 30968772
[TBL] [Abstract][Full Text] [Related]
18. [A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis].
Nakamoto K; Obata T; Hirasawa A; Kim KI; Kim SR; Tokuyama S
Yakugaku Zasshi; 2016; 136(4):583-9. PubMed ID: 27040343
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
Scorletti E; Byrne CD
Mol Aspects Med; 2018 Dec; 64():135-146. PubMed ID: 29544992
[TBL] [Abstract][Full Text] [Related]
20. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease.
Del Ben M; Polimeni L; Baratta F; Pastori D; Angelico F
Br J Clin Pharmacol; 2017 Jan; 83(1):88-95. PubMed ID: 26852185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
